MAP Pharmaceuticals News

MAP Pharmaceuticals, Inc. today announced that the Company will present at the Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 9, 2008, at 10:20 am in New York City.

Main Category: Headache / Migraine Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 15 Jul 2008 - 0:00 PDT printer friendly view / write opinions rate article ...

MAP Pharmaceuticals Inc., the Mountain View, Calif., drug developer, reported progress with MAP0004, an inhaled medication designed to treat migraines.

Main Category: Headache / Migraine Also Included In: Pharma Industry / Biotech Industry Clinical Trials / Drug Trials MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals, Inc. today announced that Telesso Technologies Limited, formerly Eiffel Technologies Limited , has agreed to transfer and assign to MAP Pharmaceuticals previously licensed intellectual ...

MAP Pharmaceuticals Inc., of Mountain View, Calif., named Marco F. Rosa vice president of human resources.

A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com . A replay will also be available within 24 hours for seven ... via Earth Times

“We are pleased with the progress we have made during the first quarter”

MAP Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2008. via Med Ad News

“We are pleased to have secured this additional capital to support our clinical development activities for pediatric asthma and migraine”

Map Pharmaceuticals Inc. said Wednesday it secured a $20 million working capital loan. via Silicon Valley / San Jose Business Jo...

“The resultsdemonstrate our ability to apply our proprietary technologies to combine two drugs within a single particle in a pre-specified ratio and deliver them to the lung”

Shares of MAP Pharmaceuticals, Inc. are slightly higher on news after the close on Monday that a stage 2 clinical trial of a drug for the treatment of asthma and chronic obstructive pulmonary disease showed ... via All Stories

“The results of our Phase 2a trial with MAP0005 demonstrate our ability to apply our proprietary technologies to combine two drugs within a single particle in a pre-specified ratio and deliver them to the lung”

MAP Pharmaceuticals, Inc. , today announced positive results from a Phase 2a clinical study evaluating MAP0005 for the potential treatment of asthma and chronic obstructive pulmonary disease . via BioSpace

“These results are consistent with our previous clinical studies, and we believe provide additional support for the safety of our next generation pediatric asthma therapy.”

Main Category: Respiratory / Asthma Also Included In: Pediatrics / Children's Health Pharma Industry / Biotech Industry MAP Pharmaceuticals, Inc. via MediLexicon

“In 2007, positive results in two Phase 2 programs allowed us to focus our resources on planning for the advancement of our pediatric asthma and migraine drug candidates into late-stage clinical trials”

The net loss for the fourth quarter and year ended December 31, 2007 was $14.9 million and $40.1 million, respectively, compared with $8.5 million and $25.8 million during the same periods in 2006. via Earth Times

Gurus Trades with MAPP: Click to exclude managers not in the List of Gurus. *The price and date might not be the actual time and price at which the transactions were made. via GuruFocus.com

“Following the positive results we saw in our Phase 2 trials, we are pleased to now have agreement with the FDA on the protocol for our first Phase 3 clinical trial to evaluate MAP0004 in migraine”

MAP Pharmaceuticals has completed the special protocol assessment process with FDA for the first Phase 3 clinical trial of its MAP0004 product candidate, and has reached agreement with the Agency on the design ... via EMaxHealth

Valley's top IPOs for 2007 Stock values soared for these valley companies. VMware, up 193 percent since Aug. via San Bernardino County Sun